Advertisement
UK markets close in 57 minutes
  • FTSE 100

    8,353.75
    -16.58 (-0.20%)
     
  • FTSE 250

    20,682.11
    -27.96 (-0.14%)
     
  • AIM

    803.61
    -0.26 (-0.03%)
     
  • GBP/EUR

    1.1733
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.2713
    -0.0007 (-0.05%)
     
  • Bitcoin GBP

    53,483.66
    -1,309.21 (-2.39%)
     
  • CMC Crypto 200

    1,477.32
    -25.34 (-1.69%)
     
  • S&P 500

    5,313.74
    +6.73 (+0.13%)
     
  • DOW

    39,386.83
    -284.21 (-0.72%)
     
  • CRUDE OIL

    78.08
    +0.51 (+0.66%)
     
  • GOLD FUTURES

    2,354.80
    -38.10 (-1.59%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     
  • DAX

    18,693.44
    +13.24 (+0.07%)
     
  • CAC 40

    8,113.94
    +21.83 (+0.27%)
     

NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14

NeuroOne Medical Technologies Corp
NeuroOne Medical Technologies Corp

EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update.

Conference Call and Webcast Information:

Tuesday, May 14, 2024 – 4:30 PM Eastern Time

Participant Dial-In:
Toll Free: 888-506-0062
International: 973-528-0011
Access Code: 489972

ADVERTISEMENT

Live Webcast: 
Join here.   

Phone Replay:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 50624
Available through May 28, 2024

Webcast Replay:
Available for 12 months

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

Contact:
800-631-4030
ir@nmtc1.com